All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), durvalumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
0.88 [0.71 ; 1.10 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 44% 1,071 moderate not evaluable progression or deaths (PFS)detailed results MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
0.87 [0.59 ; 1.29 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 325 NA not evaluable objective responses (ORR)detailed results MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
0.91 [0.58 ; 1.43 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 325 NA not evaluable AE (any grade)detailed results MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
0.54 [0.31 ; 0.94 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
0.84 [0.66 ; 1.08 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable AE leading to death (grade 5)detailed results MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
0.80 [0.42 ; 1.55 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
0.73 [0.51 ; 1.05 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
1.10 [0.64 ; 1.89 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable SAE (any grade)detailed results MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.22 [0.77 ; 1.94 ] MYSTIC (D ; PDL1>25%), 2020 1 0% 314 NA not evaluable STRAE (any grade)detailed results MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.50 [0.34 ; 0.74 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable STRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.48 [0.28 ; 0.84 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE (any grade)detailed results MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.23 [0.17 ; 0.32 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.35 [0.26 ; 0.47 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable TRAE leading to death (grade 5)detailed results MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
0.71 [0.16 ; 3.23 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.52 [0.33 ; 0.83 ] MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 1,035 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.28 [0.60 ; 2.75 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Anaemia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Asthenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.12 [0.01 ; 0.94 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Colitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Constipation TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.48 [0.02 ; 14.24 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
0.95 [0.13 ; 6.81 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Fatigue TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.81 [0.27 ; 2.45 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
3.83 [0.17 ; 85.25 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Nausea TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.02 [0.00 ; 0.18 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
3.85 [0.43 ; 34.59 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pruritus TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Rash TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.88 [0.30 ; 27.79 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Vomiting TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Anaemia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
0.16 [0.07 ; 0.34 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Asthenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
0.95 [0.41 ; 2.23 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Back pain AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
0.32 [0.03 ; 3.05 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Constipation AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
0.95 [0.06 ; 15.31 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Cough AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
1.44 [0.40 ; 5.14 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
0.38 [0.07 ; 1.96 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
1.61 [0.58 ; 4.47 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Fatigue AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
1.20 [0.47 ; 3.07 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Nausea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.16 [0.02; 1.31]
0.16 [0.02 ; 1.31 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.07 [0.02; 0.24]
0.07 [0.02 ; 0.24 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 5.76 [0.29; 115.45]
5.76 [0.29 ; 115.45 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Rash AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.88 [0.30 ; 27.79 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.05 [0.01; 0.38]
0.05 [0.01 ; 0.38 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Vomiting AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.54 [0.16; 1.86]
0.54 [0.16 ; 1.86 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.88 [0.30 ; 27.79 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-24 00:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 374,1073
